Allakos, Inc.

Allakos, Inc.

Allakos, Inc.

Overview
Date Founded

2012

Headquarters

75 Shoreway Road Suite A San Carlos CA 94070

Type of Company

Public

Employees (Worldwide)

39

Industries

Pharmaceuticals
Hospitals & Patient Services
Holding Companies
Biotechnology

Company Description

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Website
Executives & Employees

Co-Founder

President, Chief Executive Officer & Director

Chief Operating Officer & Chief Financial Officer

Chief Business Officer

Vice President-Regulatory Affairs & Drug Development

Vice President-Clinical Operations

Chief Medical Officer

Board of Directors

Managing Director at RiverVest Venture Management LLC

Co-Founder at Allakos, Inc.

President & Vice President at Alta Partners III, Inc.

Partner, Menlo Park at NEA Management Co. LLC

Executive Chairman & Chief Executive Officer at Pionyr Immunotherapeutics, Inc.

President, Chief Executive Officer & Director at Allakos, Inc.

Paths to Allakos, Inc.
Potential Connections via
Relationship Science
You
Allakos, Inc.
Recent Transactions
Details Hidden

Allakos, Inc. raised money in a private placement transaction

Details Hidden

Allakos, Inc. raised money in a private placement transaction

Advisors & Consultants
Legal Advisor

Partner at Morrison & Foerster LLP

Key Stats and Financials As of 2017
Market Capitalization
Total Enterprise Value
Earnings Per Share
$-0.58
Total Equity
$84.2M
Total Debt
$0
EBITDA
$-22M
Net Profit
$-23.6M
Revenue
$0
Investors
Details Hidden

Roche Ventures is an innovation-driven investor in the healthcare sector and has a very long-term investment horizon. The firm's sole investment theme is pharmaceutical innovation leading the prevention, diagnosis and treatment of diseases.The firm takes significant participations in companies with a view to actively support the discovery and development of innovative technologies and medicines, eventually leading to market release with a time horizon of up to several years. Exchange listing may be involved. Portfolio companies include early stage biotech and diagnostics companies. Roche Ventures is a supportive and pro-active investor.

Details Hidden

RiverVest Venture Management focuses on investments in early-stage life sciences companies with emphasis on the medical device and biopharmaceutical industries. To diversify risk and maximize portfolio returns, the firm may occasionally invest in select later-stage life science companies. RiverVest takes a hands-on investment approach and prefers to be represented on the boards of their portfolio companies.

Details Hidden

Alta Partners Management Corp. specializes in investments in healthcare venture capital companies. The firm looks for Technology enabled solutions and services that improve delivery and quality of care with Strong entrepreneurs